CRL criver.com: Quick Liquidity Indicator

Charles River Laboratories (CRL) possesses exceptional market influence due to its monopoly in the supply of animals for testing, which guarantees the company significant pricing power. The current level of quick liquidity, marked by the 1.05 parameter, confirms the financial stability of the company, whose authority in preclinical research is recognized by leading pharma behemoths. The business relies on stable demand, remaining independent of economic cycles.

CRL: Charles River Laboratories International, Inc. Intermediate Liquidity Ratio 07/04/2022 - 10/29/2026

Summary analytical data breakdowns for criver.com (CRL)

- share price and expert price forecast:

Stock Price Charles River Lab|CRL - Analyst Consensus Forecast

- company stock capitalization data:

Market Valuation Charles River Lab|CRL - Value Adjusted for Debt and Cash

- book capitalization indicators:

Accounting Value per Share Charles River|CRL - Total Net Assets|Market Capitalization to Book Value Ratio criver.com|CRL - Company Assets

- business debt structure and liquidity details:

- earnings and valuation multiples information:

CRL - Final Profit

Fundamental company valuation:Charles River Laboratories

Manufactured product of Charles River Laboratories International, Inc.

This metric measures the ability of Charles River Laboratories (CRL) to instantaneously settle short-term liabilities using only cash and accounts receivable, excluding slow-moving inventories. By analyzing the quick ratio, an investor assesses the financial stability of Charles River Laboratories (CRL), which is supported by its status as an indispensable operator in the drug development chain and consistently high demand for its high-margin services.

Competitors of Charles River Laboratories (CRL)